Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide |
Apr 2020 |
Blood Advances |
Aplastic Anemia |
Guideline-based indicators for adult patients with myelodysplastic syndromes |
Aug 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial |
Jun 2019 |
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
Granulocyte transfusions in severe aplastic anemia |
Dec 2023 |
Haematologica |
Aplastic Anemia |
Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes |
Aug 2020 |
Cancer |
Myelodysplastic Syndromes (MDS) |
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse |
Jul 2020 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Getting personal with myelodysplastic syndromes: is now the right time? |
Apr 2019 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT |
Oct 2023 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
Germline mutations in MDS/AML predisposition disorders |
Mar 2021 |
Current opinion in hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Germline DDX41 mutations define a significant entity within adult MDS/AML patients |
Sep 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |